

HEALTH RESEARCH INSTITUTE
SANTIAGO DE COMPOSTELA

ANNUAL REPORT 2020



EDITION AND PRODUCTION

Scientific-Technical Coordination of the
Health Research Institute of Santiago de Compostela.

Yolanda Liste Martínez.
Technical Management.

José Ramón Castro Ruibal.
Technical Research Management and Promotion.

APPROVAL

IDIS Board of Directors Meeting
Santiago de Compostela, on 18 May 2021.



ANNUAL REPORT 2020

INSTITUTO DE INVESTIGACIÓN SANITARIA
SANTIAGO DE COMPOSTELA

MEMORIA IDIS 2020
IDIS 2020 REPORT



Presentar a actividade que todos os membros do Instituto de Investigación Sanitaria de Santiago (IDIS) levaron a cabo é unha obriga anual e, sen dúbida, unha satisfacción xa que conseguimos sobrevivir con éxito durante este especial, duro e complicado ano 2020 que nos tocou vivir. Non foi doado para ningún de nós e todos deixamos de lado outros obxectivos para esforzarnos por manter a nosa actividade no Instituto.

José Castillo Sánchez

Director científico
Scientific Director

Platón dixo que cada bágoa nos ensina unha verdade, e a verdade é que, unha vez máis, podemos estar orgullosos e presumir colectivamente de que, a pesar das múltiples restricións e dificultades derivadas da pandemia, cumprimos. O éxito vén da loita contra os obstáculos; sen obstáculos non hai éxito real, e demostrámolo.

Alcanzamos os tres obxectivos institucionais principais que nos propuxemos este ano: a reacreditación do Instituto, o vínculo entre a Fundación e o Instituto e a sinatura do acordo IDIS entre a Consellería de Sanidade e a Universidade de Santiago de Compostela. Este triplo obxectivo abre o camiño a novos retos máis ambiciosos.

A pandemia supuxo, e segue a facelo, un inmenso custo humano, económico e profesional. Co esforzo de todos, conseguimos superar con éxito estes tres riscos. Resistimos a enfermidade e a maioría de nós xa tivemos a sorte de recibir a vacina e, como podemos ver nas páxinas seguintes, mantivemos e superamos os obxectivos económicos e profesionais.

Presenting the activity that all the members of the Health Research Institute of Santiago de Compostela (IDIS) have carried out is an annual obligation and, without a doubt, a satisfaction since we have managed to successfully survive during this specially hard and complicated year 2020.. It has not been easy for any of us, and we all had to set aside other objectives to maintain our activity at the Institute. Platon said that each tear teaches us a truth, and the truth is that - once again - we can be proud and collectively claim that, despite the multiple restrictions and difficulties arising from the pandemic, we have fulfilled our duty. Success comes from the struggle against obstacles; without obstacles there is no real success, and we have proven it.

We have achieved the three main institutional goals that we set ourselves for this year: the re-accreditation of the Institute, the link between the Foundation and the Institute and the signature of the IDIS agreement between the Department of Health and the University of Santiago de Compostela.

A pandemia tamén sensibilizou á sociedade sobre a necesidade de investigación como forma de progreso; non queda outra. A ausencia dun importante tecido investigador demostrou a debilidade da nosa economía. Debemos evitar que este clamor se perda. Débese revisar e aumentar a nosa capacidade de comunicación social. Os investigadores non son un problema, nós somos a solución. A sociedade e os seus representantes políticos non poden mirar, unha vez máis, para outro lado.

Pero non podemos estar satisfeitos co conseguido; se o fixemos, temos a obriga de fixarnos retos máis altos e traballar cara eles. A dignidade laboral e económica de todo o persoal científico e de xestión dedicado á investigación, aínda que non é unha responsabilidade directa do Instituto, é unha obriga colectiva conseguilo.

A integración do IDIS co Hospital é outro desafío emocionante. Hai demasiados profesionais que consideran o Instituto como un enxerto prescindible e, con todo, se o que representa o IDIS non o asume todo o persoal administrativo e asistencial, o Hospital nunca será excelente. A investigación non é máis que cuestionar de xeito persistente se o que facemos non se pode facer mellor e, se os prestadores de servizos de saúde non teñen este obxectivo na súa propia identidade, posiblemente acabarán facendo unha práctica clínica mellorable e ás veces perigosa.

A investigación é unha carreira competitiva sen fin, polo que todos os grupos de investigación deben mellorar os seus obxectivos e resultados. Debemos proporcionar axuda, pero tamén esixir, para que os grupos de investigación emerxentes se consoliden, e se convertan en excelentes grupos de referencia nacional e internacional.

Un grave problema que padecemos é a nula dispoñibilidade de espazos de investigación; A pesar dos traballos emprendidos e que seguiremos facendo, os espazos apenas aumentan, mentres que temos a sorte de ter un aumento exponencial no número de

This triple objective paves the way for new andmore ambitious challenges.

The pandemic has entailed, and still does, an immense human, economic and professional cost. With everyone's effort, we have managed to successfully overcome these three risks. We have weathered the disease and most of us have already been fortunate to receive the vaccine, and as we can see in the following pages, we have maintained and exceeded our financial and professional goals.

The pandemic has also raised awareness among society to the need for research as a form of progress; there is no other way about it. The absence of an important research network has exposed the weakness of our economy. We must not forget this outcry. We must review and increase our capacity for social communication. Researchers are the problem, we are the solution. Society and its political representatives cannot look the other way once again.

But we cannot be satisfied with what has been achieved; if we've done so, we have an obligation to set ourselves higher challenges and work towards them. Dignifying economic and working conditions of all scientific and management personnel dedicated to research, despite not being a direct responsibility of the Institute, is a collective obligation to achieve it.

The integration of IDIS with the Hospital is another exciting challenge. There are too many professionals who consider the Institute as a dispensable graft, and yet, if what the IDIS represents is not accepted by all clinical and administrative personnel, this Hospital will never achieve excellence. Research is nothing more than persistently questioning whether what we do can be done better, if health professionals do not have this objective in their own identity, they will possibly end up doing an improvable and sometimes dangerous clinical practice.

Research is a never-ending competitive race, so all research groups must improve their objectives and results.



investigadores. Esta ausencia de laboratorios impide o crecemento do IDIS, o desenvolvemento de proxectos máis ambiciosos e a converxencia cos obxectivos europeos e internacionais e, sen dúbida, diminúe o noso atractivo.

A nosa sociedade evoluciona rapidamente. Non podemos deixar asuntos por resolver no futuro que está por vir. O futuro xa chegou.

We must provide help, but must also be demanding, so that emerging research groups become consolidated, and become groups of excellence of national and international reference.

A serious problem that we suffer is the lack of available research space. Despite the construction works that we have undertaken, and will continue to do, available space is barely increasing, while we are fortunate to have an exponential increase in the number of researchers. This absence of laboratorie space stifles the growth of the institute, the development of more ambitious projects, convergence with European and international objectives, and, without a doubt, it diminishes our attractiveness.

Our society is evolving rapidly. We cannot leave issues to be solved in future days to come. The future is already here.

12 EXECUTIVE SUMMARY

16 GLOBAL ANALYSIS

38 STRUCTURE

50 RECURRENT TRAINING

52 INNOVATION AND TRANSFER

60 PLATFORMS

SUMMARY

68 FUNDING


72 STRATEGIC ALLIANCES

76 AREAS

86 BALANCE

EXECUTIVE SUMMARY

The **Biomedical Research Institute of Santiago de Compostela** is a translational research centre for innovation and transfer knowledge that optimizes existing synergies between the *Área Sanitaria de Santiago de Compostela and the Universidade de Santiago de Compostela* and the *University of Santiago de Compostela*. It is accredited as a medical research centre of the *National Health System by the Institute of Health Carlos III*.







2020

TOTAL FUNDS RAISED

31.340.578,96 €

88
Projects

97
Donations

114
Clinical trials

60
Staff contracts

438
Contracts and provision of services

242
Other studies

921
Published articles

67
Thesis

18
Granted patents

59
Requested patents



GLOBAL ANALYSIS


Number of **groups per area**

1.347 people are integrated in **95 groups** organized in **6 research areas.**

There is also a support area *(Scientific-Technical Coordination and common support platforms for research).*

110 researcher funded bycompetitive calls and research networks


- Oncology
- Genetics and Systems Biology
- Endocrinology
- Neurosciences
- Platforms and Methodology
- Inflammation





History of a joint venture: **human resources in figures**


1.347 people










Senior Researchers
Predoctoral Researchers
47,96%
23,87%
21,86%
6,36%
Support Staff
Posdoctoral Researchers


936
1.064
1.071
1.280
1.347
62%
38%
65%
35%
69%
31%
65%
35%
66,5%
33,5%
2016
2017
2018
2019
2020
60%
40%
67%
33%
70%
30%
65%
35%
65%
35%
Fundamental Researchers
Medical Staff


Number of **researchers per area**




95
groups
1.347
researchers
40
groups
697
researchers
Consolidated
37
groups
373
researchers
Emerging
18
groups
253
researchers
Clinical partners

Number of **published articles each year**

The Institute has published **921 original scientific articles, editorials and reviews** in **488 international journals** indexed in the *Journal Citation Report* with a **cumulative impact factor** of **5.458,4 points.**
2020: 765 original / 116 revision / 40 editorial




Cumulative **impact factor**

The upward trend of the cumulative impact factor is maintained and it moves **from 1.308 in 2010 to 5.458,4 in 2020**.




Average **impact factor**




Number of **published articles in the first decile**

A remarkable increase in the first decile for the same period from **68 articles published in 2010 to 176 in 2020**.




Number of **articles** **by year published in each quartile**



Number and % of **the total number of publications and articles in 2020**

The number of articles per quartile **increased gradually during the period of 2010-2020 almost in every quartile and every year**.


Taking into account the relevance of the authors in the articles signature, we identify those in which the first or the last author is assigned to an IDIS group. We define them as articles of our own.



Number and % of articles published in collaboration between IDIS groups and groups of centres outside of Spain.

In 2020, **21,3%** of the work were carried out by teams in which members of more than one IDIS group were involved.

45,8% were done in collaboration with researchers from centres outside of Spain.



Articles published in collaboration

423

Articles published in collaboration **between groups of centres outside of Spain**.

195

Articles published in collaboration **between IDIS groups**.





During 2020, funds raised in competitive calls for **research projects**, the **recruitment of staff**, **infrastructures**, **agreements**, **contracts and provision of services**, **donations**, **clinical trials and observational studies** generated **31.340.578,96 €** which will complement the resources of the institutions that take part in IDIS.

AMOUNT

31.340.578,96 €

Summary of **the funds raised in 2020**

CONCEPT	NUMBER	AMOUNT
Projects	88	**14.267.939,46 €**
Human resources	60	**5.196.898,69 €**
Donations	97	**953.240,23 €**
Contracts and provision of services	438	**6.745.072,44 €**
Transfer	59	**0 €**
Studies *(Clinical Trials, Observational Studies)*	356	**4.177.428,14 €**


2020
AMOUNT RAISED

31.340.578,96 €





31.340.578,96 €
32.402.824 €
32.208.340 €
29.108.535 €
23.638.401 €
2016
2017
2018
2019
2020

Number and amount of **funds raised in 2020 for projects by location**




88 Projects
14.267.939,46 €

52 Male Researcher
36 Female



Amount of **funds raised by year for projects**



114
CLINICAL TRIALS

40 National
74 International


242
OBSERVATIONAL STUDIES

111 National
29 International
27 Regional
75 Local


665 Active Clinical trials in 2020
155 Female Researchers
510 Male Researchers

16 Clinical Practice Guidelines 2020
2 Incorporated Clinical Practice Guidelines

Number of **clinical trials and observational studies**




3
STRUCTURE


BOARD OF DIRECTORS
SCIENTIFIC DIRECTION
External Scientific Committee
Internal Scientific Committee
Research Committee
Quality Committee
Primary Care Committee
Education Committee
Scientific-Technical Coordination
Fundación IDIS
USC Management and Enhancement of I+D+i Area
AREAS
GROUPS
COMMON PLATFORMS

Government bodies

BOARD OF DIRECTORS

PRESIDENT
Julio García Comesaña

VICE-PRESIDENT
Antonio López-Díaz

CHAIRS

Julián Álvarez Escudero
Ángel Carracedo Álvarez
Antonio Fernández Campa
José Ramón González Juanatey
José Luis Labandeira García
Eloína Núñez Masid
José Castillo Sánchez (without vote)
Isabel Lista García (without vote)

Advisory bodies

EXTERNAL SCIENTIFIC COMMITTEE

Ángeles Almeida Parra
Melchor Álvarez de Mon Soto
María del Carmen Ayuso García
Joan Xavier Comella Carnicé
Xosé García Bustelo
María Teresa Miras Portugal
Rosario Luquin Piudo

INTERNAL SCIENTIFIC COMMITTEE

PRESIDENT
José Castillo Sánchez

SECRETARY
José Ramón Castro Ruibal

Ezequiel Álvarez Castro
Clara Álvarez Villamarín
Ana Belén Crujeiras Martínez
Sonia Eiras Penas
Carlos González Juanatey
José Luis Labandeira García
Luis León Mateos
Isabel Lista García
Rafael López López
Mabel Loza García
Paula Mariño Lorenzo
Federico Martinón Torres
Laura Muinelo Romay
Luis Pérez de Llano
M Luisa Pérez del Molino Bernal
Daniel Rey Aldana
Mabel Sampedro Parada
Sabela da Silva Álvarez
Ana Vega Gliemmo
Irene Zarra Ferro

Advisory bodies

RESEARCH COMMITTEE

PRESIDENT
Federico Martinón Torres

SECRETARY
Yolanda Liste Martínez

José Ramón Caeiro Rey
Anxo Fernández Ferreiro
Rodolfo Gómez Bahamonde
Carlos Peña Gil
Andrés Soto Varela
Ana Vega Gliemmo
Irene Zarra Ferro
Isabel Lista García

EDUCATION COMMITTEE

PRESIDENT
Clara Álvarez Villamarín

SECRETARY
José Ramón Castro Ruibal

Ana Calvache González
Rogelio Leira Muíño
Sergio Cinza Sanjurjo
Francisca Lago Paz
María Torres Español
Ángel Díaz Lagares
Adrián Mosquera Orgueira
Diana Guallar Artal

QUALITY COMMITTEE

PRESIDENT
Luis León Mateos

SECRETARY
Yolanda Liste Martínez

Carlos Grande Sellera
Isabel Lista García
Pablo Mosquera Martínez

Advisory bodies

PRIMARY CARE COMMITTEE

PRESIDENT
Daniel Rey Aldana

SECRETARY
José Ramón Castro Ruibal

Sergio Cinza Sanjurjo
José Manuel Fernández García
José Ramón González Juanatey
Francisco Gude Sampedro
Soraya Meijome Blanco
Agustín Pía Morandeira
Manuel Portela Romero
Juan Sánchez Castro
Xoán Vázquez Lago
Sandra Yáñez Freire

SCIENTIFIC - TECHNICAL COORDINATION

José Ramón Castro Ruibal
Yolanda Liste Martínez

A001 ONCOLOGY *Coordinator:* ***Rafael López López***

C010	**Genetics of Human Diseases**	*Fernando Domínguez Puente*
C011	**Pathology**	*José Ramón Antúnez López*
C025	**NANOBIOFAR**	*María José Alonso Fernández*
C030	**Traslational Medical Oncology**	*Rafael López López*
C032	**Molecular Imaging**	*Álvaro Ruibal Morell*
E004	**Molecular Oncology**	*José Antonio Costoya Puente*
E018	**Cell Cycle and Oncology (CiClon)**	*Anxo Vidal Figueroa*
E028	**Stem Cells in Cancer and Aging**	*Manuel Collado Rodríguez*
E031	**Oncologic Endocrinology**	*Román Pérez Fernández*
E032	**Preclinical Animal Models**	*Laura Sánchez Piñón*
E033	**Viruses and cancer**	*María del Carmen Rivas Vázquez*
E037	**DNA Repair and Genome Integrity**	*Miguel González Blanco*
E042	**Translational Oncology (GIOT-HULA)**	*Cristina Núñez González*
E043	**Medical Physics and Biomathematics**	*Juan Pardo Montero*
E044	**Nano-Oncology and Translational Therapy Unit**	*María de la Fuente Freire*
AC01	**Lymphoproliferative Disorders**	*José Luis Bello López*
AC06	**Intraocular Tumours in Adults**	*Antonio Piñeiro Ces*
AC08	**Surgical Oncology**	*Manuel Bustamante Montalvo*
AC14	**Breast Patology**	*Manuel Vázquez Caruncho*
AC15	**Hematology HULA**	*Jesús Antonio Arias Sampedro*

A002 GENETICS AND SYSTEMS BIOLOGY

Coordinator: ***Ángel Carracedo Álvarez***

C005	**Genetics**	*Ángel Carracedo Álvarez*
C009	**Translational Research in Digestive Diseases**	*Juan Enrique Domínguez Muñoz*
C020	**Genetics, Vaccines, Infections and Paediatrics (GENVIP)**	*Federico Martinón Torres*
C041	**Cancer Genetics and Rare Diseases**	*Ana Paula Vega Gliemmo*
E012	**Comparative Genomics of Human Parasites**	*Julio Manuel Maside Rodríguez*
E015	**Population Genetics in Biomedicine (GenPoB)**	*Antonio Salas Ellacuriaga*
E020	**Psychiatric Genetics**	*Javier Costas Costas*
E021	**Genetics and Developmental Biology of Kidney Diseases**	*Miguel Ángel García González*
E027	**Escherichia coli**	*Jorge Blanco Álvarez*
E035	**Genetics of Gastrointestinal Tumours**	*Clara Ruiz Ponte*
E036	**Stem Cells and Human Diseases**	*Miguel Ángel Fidalgo Pérez*
E040	**Mobile Genomes and Disease**	*José Manuel Castro Tubío*
E047	**Cancer Genetics and Epidemiology Group**	*Manuela Gago Domínguez*

A003 ENDOCRINOLOGY

Coordinator: ***Felipe Casanueva Freijo***

C001	**Neoplasia and Endocrine Differentiation**	*Clara Álvarez Villamarín*
C006	**Molecular Endocrinology**	*Felipe Casanueva Freijo*
C008	**Obesity and Nutrition**	*Carlos Diéguez González*
C012	**Metabolic Disorders**	*María de la Luz Couce Pico*
C019	**Thyroid and Metabolic Disorders Unit (UETeM)**	*David Araújo Vilar*
C022	**Paediatric Nutrition**	*Rosaura Leis Trabazo*
C029	**Neurobesity**	*Miguel López Pérez*
C031	**Molecular Metabolism**	*Rubén Nogueiras Pozo*
E006	**Cytokines and Obesity (Citobes)**	*María del Carmen García García*
E023	**Obesidomics**	*María Pardo Pérez*
E025	**Cellular Endocrinology**	*Jesús Pérez Camiña*
E026	**Endocrine Physiopathology**	*Luisa María Seoane Camino*
E039	**Diabesity**	*Sulay Tovar Carro*
E041	**Epigenomics in Endocrinology and Nutrition**	*Ana Belén Crujeiras Martínez*
AC04	**Paediatric Endocrinology**	*Manuel Pombo Arias*
AC16	**Lipid Unit and Vascular Risk**	*José Ignacio Vidal Pardo*

A004 NEUROSCIENCES

Coordinator: ***José Castillo Sánchez***

C004	Neurobiology	*Antonio Canedo Lamas*
C007	Clinical Neurosciences (LINC)	*José Castillo Sánchez*
C015	Neurobiology of the Visual System	*Francisco González García*
C018	Experimental Neurology of Parkinson´s Disease	*José Luis Labandeira García*
C026	BIOFARMA	*María Isabel Loza García*
C033	Design, Synthesis and Medical Evaluation of Bioactive Compounds and New Materials	*Antonio Mouriño Mosquera*
C034	Physics of Polymers and Colloids	*Victor Mosquera Tallón*
C035	R&D in Drugs Dose Forms and Delivery Systems	*Ángel Concheiro Nine*
C036	Magnetism and Nanotechnology (NanoMag)	*José Rivas Rey*
C037	Trace Elements, Spectroscopy and Speciation	*Pilar Bermejo Barrera*
C038	Analytical Chemistry of Compounds of Alimentary, Environmental and Biological Interest	*Antonia María Carro Díaz*
E014	Prion Diseases	*Jesús Rodríguez Requena*
E019	Cell Stress	*Juan Bautista Zalvide Torrente*
E029	Cognitive Neuroscience	*Fernando Díaz Fernández*
AC03	Critical Patient	*Julián Álvarez Escudero*
AC11	Life Support and Medical Simulation	*Antonio Rodríguez Núñez*
AC12	Otoneurology	*Marcos Rossi Izquierdo*

A005 PLATFORMS AND METHODOLOGY

Coordinator: ***Francisco Gude Sampedro***

C002	**Experimental Surgery**	*Miguel Ángel Caínzos Fernández*
C013	**Epidemiology, Public Health and Evaluation of Health Services**	*Adolfo Figueiras Guzmán*
C017	**Research Methodology**	*Francisco Gude Sampedro*
C021	**Clinical Analysis**	*Santiago Rodríguez-Segade Villamarín*
C024	**Radiology**	*Miguel Souto Bayarri*
E002	**Biostatistics**	*Carmen María Cadarso Suárez*
E013	**Microbiology**	*María Luisa Pérez del Molino Bernal*
E034	**Clinical Pharmacology**	*María Jesús Lamas Díaz*
E046	**PARAQUASIL**	*José Blanco Méndez*
AC09	**Oral Sciences (OSRG)**	*Inmaculada Tomás Carmona*
AC10	**Healthy ageing, fragility and chronicity. Research in Primary Care**	*Juan Manuel Vázquez Lago*
AC13	**Dermatology and Craniofacial Pathology (DePaCra)**	*Pablo Ignacio Varela Centelles*
AC17	**Comprehensive care of the patient. Epidemiology and physiopathology of frailty**	*María Bermúdez López*
AC18	**Surgical Research (GRICI)**	*José Conde Vales*
AC19	**Vascular Research Group of Santiago (VARGROS)**	*Diego Caicedo Valdés*


A006 INFLAMMATION

Coordinator: ***José Ramón González Juanatey***

C003	**Hypertension**	*Carlos Calvo Gómez*
C014	**Rheumatology**	*Juan Jesús Gómez-Reino Carnota*
C016	**Cardiology**	*José Ramón González Juanatey*
C027	**Neuroendocrine Interactions in Rheumatic and Inflammatory Diseases (Neirid)**	*Oreste Gualillo*
C028	**Experimental and Observational Rheumatology**	*Antonio González Martínez-Pedrayo*
C039	**Biodiscovery HULA-USC**	*Luis Miguel Botana López*
C040	**Oral Medicine and Surgery (OMEQUI)**	*Pedro Diz Dios*
E001	**Cardiovascular Genetics**	*María José Brión Martínez*
E009	**Cellular and Molecular Cardiology**	*Francisca Lago Paz*
E030	**Platelet Proteomics**	*Ángel García Alonso*
E038	**Musculoskeletal Pathology**	*Rodolfo Gómez Bahamonde*
E045	**Translational Cardiology**	*Sonia Eiras Penas*
AC05	**Pneumology**	*Luis Guillermo Valdés Cuadrado*
AC07	**Semergal**	*Sergio Cinza Sanjurjo*


RECURRENT
TRAINING

Number of **thesis each year**



67 Doctoral Theses in 2020 - 20 European Mention

43 Female PhD Student - 17 European Mention

24 Male PhD Student - 3 European Mention




IDIS. ANNUAL REPORT **2020**

INNOVATION AND TRANSFER


Transfer acceleration through public funding and private investment
Adopting the Public-Private Partnership Model
Disseminating our research
Intellectual property

Transfer acceleration through public funding and private investment



ITEMAS network

Innovation in Medical and Heath Technologies Network funded by the Instituto de Salud Carlos III.

IGNICIA

The IGNICIA Proof of Concept programme of the Galician Innovation Agency (GAIN) aims to enhance and support the transfer of research results generated by knowledge centres. IGNICIA seeks to accelerate and increase technology transfer, detecting projects with innovative and market potential, contributing to the profitability of public investment in research.


IDIS has 1 project granted.

Atlantic Ket Med

Atlantic KET Med (AKM) is an Interreg funded, coordinated action aiming to establish a Transnational Advanced Pilot Manufacturing Ecosystem for Future Biomedical Products. Featuring partners with expertise in the Key Enabling Technologies (KETs), AKM plans to provide bottom-up support to the ecosystem through direct support of SMEs as well as top-down support through educational and infrastructure policies.

IDIS joins the ecosystem and it´s the only Spanish research centre that participates in AKM.

Adopting the Public-Private Partnership Model



Two P2 ongoing initiatives where public IDIS partners share risks with private investors.

Roche-CHUS


Precision Oncology Joint Unit.

PRECISION ONCOLOGY
ROCHE|CHUS JOINT UNIT

Esteve-USC

Drug Discovery Joint Unit.

ESTEVE USC UNIVERSIDADE DE SANTIAGO DE COMPOSTELA



BioINCUBATECH

BioIncubaTech is the High Technology Incubator for the promotion of innovation and biotechnology transfer in the field of health and food technologies to micro-SMEs. BioIncubaTech belongs to "High Technology Incubators for the promotion of innovation and technology transfer to micro-SMEs" Project, aimed to modernize the regional productive fabric. These Incubators are created as traction instruments aligned with the objectives of the EU 2020 and Horizon 2020 Strategy and will promote inter-regional cooperation, as well as collaboration between public and private sector agents at international level.

IDIS collaborates since the beginning of this proposal and helped to create the project. We have 2 incubated projects.


Intelectual property

59 Request

45 International Application
3 National Application
11 PCT Application

18 Granted

1 Licensed



Trademarks

DIVERSA

galCovid

Spin off

bflow

FlowReserve
Personalized Medicine in Cardiology

QUBIO tech

NASAS BIOTECH


DART
Detection And Radiation Technologies


Lincbiotech




IDIS. ANNUAL REPORT **2020**

PLATFORMS


USC
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
CiMUS
CAMPUS VIDA
CAMPUS DE EXCELENCIA INTERNACIONAL
CESGA
9,4 Magnetic Resonance
Citometry
Microscopy
Epidemiology And Clinical Research Unit
The Animal Experimentation Unit
Sequencing And Fragment Analysis Unit
Molecular Imaging Unit Micropet/spect/ct Scan
SERVIZO GALEGO de SAÚDE



Liquid Biopsy Unit
Drug Screening Platform (Usef)
Proteomics
bugalicia
Pet Radiopharmacy Unit Galicia Cyclotron
Radiophysics Laboratory
Imaging
Experimental Biomedicine Centre (Cebega)
Bibliosaúde
Genomics
Biobank
Early clinical trials unit
Nanostring



Proteomics

Susana Belén Bravo López
susana.belen.bravo.lopez@sergas.es


The proteomics platform was created to enhance, give support and offer a complete infrastructure in the field of proteomics to the Institute's researchers and other public and private bodies. It is equipped with the latest generation technology that allows the development of both studies of characterisation of complete proteomes as well as studies of analysis of differential expression.



Liquid Biopsy Unit

Laura Muinelo Romay
laura.muinelo.romay@sergas.es

The service for the analysis of circulating cells works with the CellSearchTM system (Veridex) that allows, through the use of immunomagnetic techniques of enrichment and identification by immunofluorescence, isolate and quantify present cells in peripheral blood. Its main application is aimed to the detailed analysis of circulating tumor cells (CTC), even though the computer also allows identify other kind of cells such as endothelial. In addition, the platform has the capacity to carry out studies with circulating DNA.




Pablo Hervella Lorenzo

pablo.hervella.lorenzo@sergas.es

It is a technique of cells analysis that allows one to measure the characteristics of light scattering and fluorescence that cells have when they pass through a ray of light. This platform's main aims are:


- To advise users of the IDIS on the principles and applications of flow cytometry analysis and cell sorting.
- To develop, optimize and perform new analytic applications demanded by the users of the IDIS.
- To do cellular isolation through cell sorting.
- Quantify different soluble cytokines using multiplex tests.



Ramón Iglesias Rey

ramon.iglesias.rey@sergas.es

Magnetic Resonance Imaging is perhaps the most versatile neuroimaging technique that exists today. The use of this platform in its different variants (anatomical, functional, spectroscopy and molecular imaging) allows one to perform a complete follow-up, non-invasive (in vivo) and longitudinal in time of the process associated with neurovascular diseases and other such as plasticity, reorganization and functional recovery in animal models.




Lydia Fraga Fontoira (Manager)

biobanco.apa.santiago@sergas.es
lydia.fraga.fontoira@sergas.es

The Biobank is a transversal platform providing support to biomedical research. It is comprised of CHUS's Biobank (located in the University Hospital Complex of Santiago de Compostela) and the HULA Biobank (located in the Lucus Augusti University Hospital).


These are public and non-profit facilities in which biological samples and associated clinical information, of high quality for their use in biomedical research, are stored. They are focused on managing, under safety, quality and efficiency criteria, the reception, storage and subsequent transfer of samples to requesting researchers so they can use them in their projects, provided they meet the ethical and legal requirements.



Pablo Aguiar Fernández

pablo.aguiar.fernandez@sergas.es

Our mission is to bridge the gap between in vitro biomedical research and in vivo preclinical and clinical imaging, providing novel molecular imaging biomarkers and imaging probes to gain information about physiology and pathology in vivo. We offer a core facility to provide opportunities for in vivo molecular imaging based on PET, SPECT and CT technologies.



The Animal Experimentation Unit

Francisco Campos Pérez

francisco.campos.perez@sergas.es

The Animal Experimentation Unit provides support in biomedical research with several animal models for IDIS research groups, in strictly controlled sanitary and environmental conditions. The Animal Experimentation Unit is accredited by the Ministry of Rural Environment of the Xunta de Galicia. It has rat and mouse housing facilities, surgery rooms and specialized qualified personnel, in accordance with current regulations. It also has an Ethics Committee on Animal Experimentation. It obtained the corresponding accreditation as an Authorized Body to carry out the evaluation of projects from a scientific or educational point of view.

It is responsible for advice on issues related to animal welfare, review of internal operational processes, issuance of reports and monitoring of projects. Its objective is to promote research, and to develop and implement biomedical training, providing professionals with the necessary resources for the development of these initiatives.



Confocal Microscopy

Marta Picado Barreiro

marta.picado.barreiro@sergas.es

The confocal scanning microscope is well-known for its ability to perform optical sectioning: a thin plane or section within a thick turbid medium is non-invasively imaged with high resolution and contrast. Real-time in vivo confocal fluorescence microscopy. Nuclear, cellular and morphologic detail is imaged in living intact tissue without having to excise physically and prepare thin sections or cultures.

The services include the infrastructure and specialised staff to perform analysis as...

- 3D imaging reconstruction
- Multiple labeling
- Colocalization
- In vivo fluorescence imaging

FUNDING

TOTAL

31.340.578,96 €

88
Projects
14.267.939,46 €

60
Human resources
5.196.898,69 €

97
Donations
953.240,23 €

438
Contracts and provision of services
6.745.072,44 €

356
Studies (Clinical Trials, Other Studies)
4.177.428,14 €

During 2020, **31.340.578,96 €** were raised in the following concepts: projects, human resources, transfer, donations, contracts, infrastructures, provision of services, agreements and studies.

COMPETITIVE FUNDING

19.464.838,15 €

88
PROJECTS

14.267.939,46 €

24
Regional projects
3.574.076 €

56
National projects
7.193.349 €

8
International projects
3.500.515 €

60 Human resources

5.196.898,69 €

CONCEPT	NUMBER	AMOUNT
IDIS Predoctoral Grant	8	**540.000 €**
PFIS / iPFIS	3	**247.200 €**
GAIN Predoctoral Grant	18	**1.296.356 €**
FPI	3	**267.885 €**
FPU	6	**492.180 €**
Río Hortega	7	**376.124 €**
Juan de la Cierva	2	**149.501 €**
Sara Borrell	2	**161.196 €**
Ramón y Cajal	2	**415.224 €**
Joan Rodés	2	**360.000 €**
Miguel Servet (I/II)	3	**586.250 €**
Intensificación	2	**120.000 €**
Gestión Investigación en Salud	1	**80.598 €**
INPhINIT La Caixa	1	**104.382 €**



IDIS. ANNUAL REPORT **2020**

STRATEGIC ALLIANCES

PLATFORMS

3

RNBB. BIOBANK Network

ITEMAS ISCIII. Innovation in Medical and Health Technologies

SCREN. Spanish Clinical Research Network ISCIII

Red Biobancos
Instituto de Salud Carlos III

itemas isciii

SCReN Spanish Clinical Research Network ISCIII

CIBER

BIOMEDICAL RESEARCH NETWORKING CENTRES

6

ciberobn
ciberer
ciberesp
cibercv isciii
ciberonc isciii
ciber isciii

CIBEROBN (1), Physiopathology of Obesity and Nutrition

CIBERER, Rare Diseases

CIBERESP, Public Health and Epidemiology

CIBERCV: Cardiovascular Diseases

CIBERONC: Cancer

CIBER CIBERNED: Neurodegenerative Diseases

(1) Scientific Direction IDIS

RETICS

6

INVICTUS (1), Cerebrovascular diseases (stroke)

OFTARED, Eye Diseases

REDIAPP, Research Network on Preventive Activities and Health Promotion in Primary Care

RIER, Rheumatic Diseases

REDINREN, Kidney Diseases

TerCELL. Cell Therapy Network

(1) Scientific Direction IDIS

NETWORKS FOR COOPERATIVE RESEARCH IN HEALTH

INTERNATIONAL NETWORK

2


EATRIS, European infrastructure for translational medicine


COST, European Cooperation in Science and Technology




IDIS. ANNUAL REPORT **2020**

AREAS




A001
Oncology
254
A002
Genetics and
Systems Biology
222




1.347 PEOPLE
are integrated
in **95 groups**

6
RESEARCH
AREAS




921
Publications


Publications in 2020




$\overline{fi}$


10
8
6
4
2
5,751
8,621
5,850
4,197
3,802
6,144
Oncology
Genetics and Systems Biology
Endocrinology
Neurosciences
Platforms and Methodology
Inflammation


Σfi



2000
1500
1000
500
0
822,42
1.594,893
713,744
969,566
665,062
1.364,02
Oncology
Genetics and Systems Biology
Endocrinology
Neurosciences
Platforms and Methodology
Inflammation


Thesis



Patents









- Oncology
- Genetics and Systems Biology
- Endocrinology
- Neurosciences
- Platforms and Methodology
- Inflammation


Projects






14.267.939,46 €


Contracts






6.745.072,44 €

Clinical Studies





4.177.428,14 €



IDIS. ANNUAL REPORT **2020**


BALANCE

	ACTIVO	NOTAS	31/12/2020	31/12/2019
A)	**ACTIVO NO CORRIENTE**		**10.338.646,93 €**	**11.015.049,42 €**
I.	**Inmovilizado intangible**	**5**	**27.680,57 €**	**578,25 €**
3.	Patentes, licencias, marcas y similares		0,00 €	0,00 €
5.	Aplicaciones informáticas		27.680,57 €	578,25 €
III.	**Inmovilizado material**	**6**	**2.207.702,11 €**	**2.298.848,41 €**
1.	Terrenos y construcciones		1.236.939,52 €	1.318.869,45 €
2.	Instalaciones técnicas y otro inmovilizado material		956.219,10 €	979.978,96 €
3.	Inmovilizado en cursos y anticipos		14.543,49 €	0,00 €
VI.	**Inversiones financieras a largo plazo**	**8.1**	**8.103.264,25 €**	**8.715.622,76 €**
1.	Instrumentos de Patrimonio		8.102.364,25 €	8.714.722,76 €
3.	Valores representativos de deuda		0,00 €	0,00 €
5.	Otros activos financieros		900,00 €	900,00 €
B)	**ACTIVO CORRIENTE**		**32.671.941,65 €**	**28.569.969,38 €**
I.	**Usuarios y otros deudores de la actividad propia**	**9**	**1.504.713,65 €**	**1.272.165,29 €**
II.	**Existencias**		**110.317,40 €**	**23.217,37 €**
6.	Anticipos a proveedores		110.317,40 €	23.217,37 €
III.	**Deudores comerciales y otras cuentas a cobrar**	**9**	**12.253.354,90 €**	**11.202.830,64 €**
3.	Deudores varios		0,00 €	0,00 €
4.	Personal		0,00 €	0,00 €
5.	Activos por impuesto corriente		0,00 €	0,00 €
6.	Otros créditos con las Administraciones Pública		12.253.354,90 €	11.202.830,64 €
V.	**Inversiones financieras a corto plazo**	**8.1**	**1.500.664,59 €**	**3.918.707,89 €**
2.	Créditos a entidades		0,00 €	165.005,80 €
3.	Valores representativos de deuda		0,00 €	2.253.702,09 €
5.	Otros activos financieros		1.500.664,59 €	1.500.000,00 €
VI.	**Peridiodificaciones a corto plazo**		**19.282,16 €**	**12.520,99 €**
VII	**Efectivo y otros activos líquidos equivalentes**	**11**	**17.283.608,95 €**	**12.140.527,20 €**
1.	Tesorería		17.283.608,95 €	12.140.527,20 €
2.	Otros activos líquidos equivalentes		0,00 €	0,00 €
	TOTAL ACTIVO (A + B)		**43.010.588,58 €**	**39.585.018,80 €**

	PATRIMONIO NETO Y PASIVO		31/12/2020	31/12/2019
A)	**PATRIMONIO NETO**		**8.339.858,01 €**	**7.979.536,34 €**
A-1)	**Fondos propios**	**12**	**6.359.126,71 €**	**6.206.964,01 €**
I.	**Dotación fundacional / Fondo social**		**153.952,45 €**	**153.952,45 €**
	Dotación fundacional / Fondo social		153.952,45 €	153.952,45 €
II.	**Reservas**		**6.053.011,56 €**	**5.922.055,76 €**
	Otras reservas		6.053.011,56 €	5.922.055,76 €
IV.	**Excedente del ejercicio**		**152.162,70 €**	**130.955,80 €**
A-2)	**Ajustes por cambio de valor**		**316.208,02 €**	**153.131,71 €**
	Activos financieros disponibles para la venta		316.208,02 €	153.131,71 €
A-3)	**Subvenciones, donaciones y legados recibidos**	**17**	**1.664.523,28 €**	**1.619.440,62 €**
I.	**Subvenciones**		235.652,54 €	255.772,53 €
II.	**Donaciones y legados**		1.428.870,74 €	1.363.668,09 €
B)	**PASIVO NO CORRIENTE**		**988.915,61 €**	**763.746,54 €**
I.	**Provisiones a largo plazo**	**15**	**988.915,61 €**	**763.746,54 €**
1.	Obligaciones por prestaciones a largo plazo al personal		988.915,61 €	763.746,54 €
II.	**Deudas a largo plazo**	**8.2**	**0,00 €**	**0,00 €**
5.	Otros pasivos financieros		0,00 €	0,00 €
C)	**PASIVO CORRIENTE**		**33.681.814,96 €**	**30.841.735,92 €**
I.	**Provisiones a corto plazo**	**15**	**10.462.527,30 €**	**9.953.601,40 €**
II.	**Deudas a corto plazo**	**8.2**	**17.530.714,27 €**	**14.883.162,25 €**
3.	Acreedores por arrendamiento financiero		0,00 €	0,00 €
5.	Otras deudas a corto plazo		17.530.714,27 €	14.883.162,25 €
IV.	**Beneficiarios - Acreedores**	**10**	**0,00 €**	**0,00 €**
V.	**Acreedores comerciales y otras cuentas a pagar**	**10**	**5.688.573,39 €**	**6.004.972,27 €**
1.	Proveedores		136.717,67 €	303.578,94 €
3.	Acreedores varios		80.146,48 €	214.370,71 €
4.	Personal (remuneraciones pendientes de pago		0,00 €	0,00 €
6.	Otras deudas con las Administraciones Públicas		5.471.709,24 €	5.487.022,62 €
7.	Anticipos recibidos por pedidos		0,00 €	0,00 €
	TOTAL PATRIMONIO NETO Y PASIVO (A + B + C)		**43.010.588,58 €**	**39.585.018,80 €**

A)	Excedente del ejercicio	NOTAS	31/12/20	31/12/19
1.	**Ingresos de la actividad propia**		**15.167.067,54 €**	**14.429.819,05 €**
	b) Aportaciones de usuarios		5.272.763,32 €	5.489.850,74 €
	c) Ingresos de promociones, patrocinadores y colaboraciones	14.d	2.246.393,36 €	1.922.664,08 €
	d) Subvenciones imputados al excedente del ejercicio	17	6.798.123,52 €	6.115.824,38 €
	e) Donaciones y legados imputados al excedente del ejercicio	17	849.787,34 €	901.479,85 €
2.	**Gastos por ayudas y otros**	14.a	**-538.789,97 €**	**-302.838,64 €**
	a) Ayudas monetarias		-533.773,60 €	-294.977,98 €
	b) Reintegro de subvenciones, donaciones y legados		-5.016,37 €	-7.860,66 €
5.	**Aprovisionamientos**	14.b	**-2.006.119,96 €**	**-1.804.578,62 €**
6.	**Otros ingresos de la actividad**		**0,00 €**	**0,00 €**
7.	**Gastos de personal**		**-7.425.739,29 €**	**-6.468.294,22 €**
	a) Sueldos, salarios y asimilados		-5.582.685,27 €	-4.914.532,36 €
	b) Cargas sociales	14,c	-1.617.884,95 €	-1.538.320,66 €
	c) Provisiones		-225.169,07 €	-15.341,20 €
8.	**Otros gastos de la actividad**		**-3.942.094,77 €**	**-4.802.641,93 €**
	a) Servicios exteriores		-3.267.143,80 €	-3.782.890,65 €
	b) Tributos		-8.783,26 €	-7.558,08 €|
	c) Pérdidas, deterioro y variación de provisiones por operaciones comerciales		-666.167,71 €	-1.012.193,20 €
	d) Otros gastos de gestión corriente		0,00 €	0,00 €
9.	**Amortización del inmovilizado**		**-1.305.876,85 €**	**-1.050.746,69 €**
10.	**Subvenciones, donaciones y legados de capital traspasados al excedente del ejercicio**		**274.305,51 €**	**94.837,68 €**
	a) Subvenciones de capital traspasadas al excedente del ejercicio		163.002,32 €	90.606,68 €
	b) Donaciones y legados de capital traspasados al excedente del ejercicio		111.303,19 €	4.231,00 €
11.	**Exceso de provisiones**		**0,00 €**	**0,00 €**
12.	**Deterioro y resultado por enajenaciones del inmovilizado (a+b)**		**0,00 €**	**0,00 €**
	a) Deterioro y pérdidas		0,00 €	0,00 €
	b) Resultados por enajenaciones y otras		0,00 €	0,00 €
13.	**Resultado excepcional**		**0,00 €**	**-123,63 €**
	Ingresos excepcionales		0,00 €	0,00 €
	gastos excepcionales		0,00 €	-123,63 €
A.1)	**EXCEDENTE DE LA ACTIVIDAD (1+2+3+4+5+6+7+8+9+10+11+12+13)**		**222.752,21 €**	**95.433,00 €**
14.	**Ingresos financieros**	8.1	**26.327,63 €**	**34.184,25 €**
	b) De valores negociables y otros instrumentos financieros		26.327,63 €	34.184,25 €
	b1) De entidades del grupo y asociadas		0,00 €	0,00 €
	b2)De terceros		26.327,63 €	34.184,25 €
15.	**Gastos financieros**	8.2	**-5.184,98 €**	**-1.827,79 €**
	a) Por deudas con entidades del grupo y asociadas		0,00 €	0,00 €
	b) Por deudas con terceros		-5.184,98 €	-1.827,79 €
	c) Por actualización de provisiones		0,00 €	0,00 €
16.	**Variación de valor razonable en instrumentos financieros**		**-89.972,32 €**	**4.924,25 €**
	a) Cartera de negociación y otros		0,00 €	0,00 €
	b) Imputación al excedente del ejercicio por activos financieros disponibles para la venta		-89.972,32 €	4.924,25 €
17.	**Diferencias de Cambio**		**-190,86 €**	**-1.757,91 €**
18.	**Deterioro y resultado por enajenaciones de instrumentos financieros**		**-1.568,98 €**	**0,00 €**
	a) Deterioro y pérdidas		-1.568,98 €	0,00 €
	b) Resultados por enajenaciones y otros		0,00 €	0,00 €

A.2)	EXCEDENTE DE LAS OPERACIONES FINANCIERAS (13+14+15+16+17)		-70.589,51 €	35.522,80 €
A.3)	EXCEDENTE ANTES DE IMPUESTOS (A.1+A.2)		152.162,70 €	130.955,80 €
18.	Impuestos sobre beneficios	13	0,00 €	0,00 €
A.4)	Variación de patrimonio neto reconocida en el excedente del ejercicio (A.3 + 18)		152.162,70 €	130.955,80 €
B)	Ingresos y gastos imputados directamente al patrimonio neto**.			
1.	Activos financieros disponibles para la venta.		73.103,99 €	580.268,90 €
2.	Operaciones de cobertura de flujos de efectivo.		0,00 €	0,00 €
3.	Subvenciones recibidas.		6.941.005,85 €	6.184.191,26 €
4.	Donaciones y legados recibidos.		1.026.293,18 €	829.002,43 €
5.	Ganancias y pérdidas actuariales y otros ajustes.		0,00 €	0,00 €
6.	Efecto impositivo.		0,00 €	0,00 €
B.1)	Variación de patrimonio neto por ingresos y gastos reconocidos directamente en el patrimonio neto (1+2+3+4+5+6)		8.040.403,02 €	7.593.462,59 €
C)	Reclasificaciones al excedente del ejercicio.			
1.	Activos financieros disponibles para la venta.		89.972,32 €	-4.924,25 €
2.	Operaciones de cobertura de flujos de efectivo.		0,00 €	0,00 €
3.	Subvenciones recibidas.		-6.961.125,84 €	-6.206.431,06 €
4.	Donaciones y legados recibidos.		-961.090,53 €	-905.710,85 €
5.	Efecto impositivo.		0,00 €	0,00 €
C.1)	Variación de patrimonio neto por reclasificaciones al excedente del ejercicio (1+2+3+4+5)		-7.832.244,05 €	-7.117.066,16 €
D)	Variaciones de patrimonio neto por ingresos y gastos imputados directamente al patrimonio neto (B.1 + C.1)**		208.158,97 €	476.396,43 €
E)	Ajustes por cambios de criterio		0,00 €	0,00 €
F)	Ajustes por errores		105.953,14 €	76.104,20 €
G)	Variaciones en la dotación fundacional o fondo social		0,00 €	0,00 €
H)	Otras variaciones		0,00 €	0,00 €
I)	RESULTADO TOTAL, VARIACIÓN DEL PATRIMONIO NETO EN EL EJERCICIO (A.4+D+E+F+G+H)		466.274,81 €	683.456,43 €


idis

ANNUAL REPORT **2020**


idis
USC
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
XUNTA DE GALICIA
CONSELLERÍA DE SANIDADE